Capstone Investment Advisors
MRNA icon

Capstone Investment Advisors’s Moderna MRNA Stock Holding History

Capstone Investment Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3M Buy
379,100
+6,500
+2% +$303K 0.03% 180
2025
Q4 		$11M Sell
372,600
-283,700
-43% -$7.71M 0.02% 254
2025
Q3 		$17M Buy
656,300
+612,200
+1,388% +$17.1M 0.03% 227
2025
Q2 		$1.22M Sell
44,100
-6,200
-12% -$163K ﹤0.01% 790
2025
Q1 		$1.43M Sell
50,300
-18,000
-26% -$639K ﹤0.01% 781
2024
Q4 		$2.84M Sell
68,300
-68,100
-50% -$3.25M 0.01% 731
2024
Q3 		$9.12M Buy
136,400
+9,400
+7% +$863K 0.03% 317
2024
Q2 		$15.1M Buy
127,000
+53,100
+72% +$6.72M 0.05% 232
2024
Q1 		$7.87M Buy
73,900
+2,600
+4% +$262K 0.03% 318
2023
Q4 		$7.09M Sell
71,300
-7,500
-10% -$631K 0.02% 424
2023
Q3 		$8.14M Buy
78,800
+14,500
+23% +$1.62M 0.04% 321
2023
Q2 		$7.81M Buy
64,300
+9,000
+16% +$1.2M 0.04% 285
2023
Q1 		$8.49M Sell
55,300
-13,800
-20% -$2.28M 0.04% 263
2022
Q4 		$12.4M Buy
69,100
+7,900
+13% +$1.29M 0.09% 184
2022
Q3 		$7.24M Sell
61,200
-19,900
-25% -$3.02M 0.04% 310
2022
Q2 		$11.6M Sell
81,100
-145,500
-64% -$20.8M 0.06% 227
2022
Q1 		$39M Buy
226,600
+95,900
+73% +$16.1M 0.11% 142
2021
Q4 		$33.2M Buy
130,700
+32,100
+33% +$9.39M 0.06% 302
2021
Q3 		$37.9M Buy
+98,600
New +$36.4M 0.08% 246
2021
Q1 		– Sell
-54,300
Closed -$5.67M – 1867
2020
Q4 		$5.67M Sell
54,300
-38,500
-41% -$3.89M 0.02% 553
2020
Q3 		$6.57M Buy
+92,800
New +$6.47M 0.03% 437

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capstone Investment Advisors's MRNA Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Moderna (MRNA) in Q1 2026: 5,755 shares worth $292K. The stake represents ﹤0.01% of the portfolio and ranks #1371 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in MRNA as recently as Q3 2025.

Capstone Investment Advisors first reported a position in MRNA in Q3 2020 and has held it in 19 quarters since. The position peaked at $10.4M in Q4 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Capstone Investment Advisors held 5,755 shares of Moderna worth $292K as of Q1 2026.
  • Moderna was a new Capstone Investment Advisors position in Q1 2026.
  • Moderna made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1371 holding.
  • Capstone Investment Advisors first reported a position in Moderna in Q3 2020 and has held it in 19 quarters since.
  • Capstone Investment Advisors's Moderna position peaked at $10.4M in Q4 2021.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.